Wall Street Zen Upgrades Capricor Therapeutics (NASDAQ:CAPR) to “Hold”

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

CAPR has been the subject of several other research reports. Oppenheimer upped their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Maxim Group boosted their price target on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Industrial Alliance Securities set a $48.00 price target on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Monday, December 15th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.82.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $28.31 on Friday. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37. The stock has a market capitalization of $1.29 billion, a PE ratio of -15.73 and a beta of 0.22. The firm has a 50 day simple moving average of $16.05 and a 200-day simple moving average of $10.51.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). On average, analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. Goldman Sachs Group Inc. increased its stake in Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after purchasing an additional 116,373 shares in the last quarter. Octagon Capital Advisors LP acquired a new position in shares of Capricor Therapeutics in the first quarter worth about $4,270,000. Woodline Partners LP increased its position in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock worth $6,921,000 after acquiring an additional 99,384 shares in the last quarter. Rhumbline Advisers increased its position in shares of Capricor Therapeutics by 8.1% in the first quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company’s stock worth $473,000 after acquiring an additional 3,731 shares in the last quarter. Finally, Krilogy Financial LLC raised its holdings in shares of Capricor Therapeutics by 78.9% during the second quarter. Krilogy Financial LLC now owns 40,800 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 18,000 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.